Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 223, Issue 3, Pages 370-380Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiaa377
Keywords
monoclonal antibodies; broadly neutralizing antibodies; HIV; clinical trials
Categories
Funding
- European and Developing Countries Clinical Trials Partnership [RIA2017S]
- South African Medical Research Council's Special Initiative on HIV Prevention Technology
Ask authors/readers for more resources
Passive immunization with bnAbs shows potential in reducing global HIV infections, with newly developed highly potent bnAbs showing promise for HIV prevention. Published data indicate these antibodies are safe and effective, and if proven to be successful, could have a positive impact on HIV vaccine development.
Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally. Early studies on bnAbs showed safety in humans, but short elimination half-lives and low potency and breadth. Since 2010, several new highly potent bnAbs have been assessed in clinical trials alone or in combination for HIV prevention. Published data indicate that these bnAbs are safe and have a half-life ranging from 15 to 71 days. Only intravenous VRC01 has advanced to an efficacy trial, with results expected in late 2020. If bnAbs are shown to be effective in preventing HIV infection, they could fast-track vaccine development as correlates of protection, and contribute as passive immunization to achieving the goal of epidemic control. The purpose of the current review is to describe the current status and provide a synopsis of the available data on bnAbs in clinical trials for HIV prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available